Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2009
03/19/2009US20090075931 isotope exchanged capecitabine, used for the treatment of metastatic breast cancer; anticarcinogenic agents
03/19/2009US20090075930 for treating leukemia
03/19/2009US20090075922 Nucleic Acid Ligands Which Bind to Hepatocyte Growth Factor/Scatter Factor (HGF/SF) or its Receptor c-met
03/19/2009US20090075919 Anti-neoplastic compositions comprising extracts of black cohosh
03/19/2009US20090075905 Anticancer compounds and methods
03/19/2009US20090075901 treatment of cell damage caused by ischemia or stroke by administering to a cell or a tissue an effective amount of an isozyme specific delta PKC (protein kinase C) antagonist
03/19/2009US20090075889 Iren protein, its preparation and use
03/19/2009US20090075886 Dendritic cell stimulatory factor
03/19/2009US20090075883 Compositions for the treatment of cancer, and methods for testing and using the same
03/19/2009US20090075878 Methods for Generating and Screening Fusion Protein Libraries and Uses Thereof
03/19/2009US20090075876 Altered insulin-like growth factor binding proteins
03/19/2009US20090075871 Modified Thioredoxin
03/19/2009US20090075867 Triazine compounds and compositions thereof for the treatment of cancers
03/19/2009US20090075327 Methods for improving secondary metabolite production in fungi
03/19/2009US20090075302 Compositions and methods for the diagnosis and treatment of tumor
03/19/2009US20090075279 Compositions and methods for the diagnosis and treatment of tumor
03/19/2009US20090075278 Compositions and methods for the diagnosis and treatment of tumor
03/19/2009US20090074896 Extracts of Polygonum multiflorum Thunb, and preparation process and uses of the same
03/19/2009US20090074891 Combretum laurifolium mart. extract and methods of extracting and using such extract
03/19/2009US20090074885 Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells
03/19/2009US20090074884 Family of pfkfb3 inhibitors with anti-neoplastic activities
03/19/2009US20090074870 Alteration of cell membrane for new functions
03/19/2009US20090074859 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
03/19/2009US20090074852 Lipoplex formulations for specific delivery to vascular endothelium
03/19/2009US20090074849 Cancer-suppressing agents
03/19/2009US20090074830 Anti-angiogenic compositions and methods of use
03/19/2009US20090074816 Tissue targeted antigenic activation of the immune response to cancers
03/19/2009US20090074800 Cancer antigen and use thereof
03/19/2009US20090074794 for use in the treatment of crohn's and ulcerative colitis; administering a composition comprising an effective amount of at least one isolated mammalian anti-tumor necrosis factor (TNF) antibody comprising at least one variable region comprising SEQ ID NO:7 and 8
03/19/2009US20090074788 Antibody Against Periostin, and a Pharmaceutical Composition comprising it for Preventing or Treating a Disease in which Periostin is Involved
03/19/2009US20090074785 Compositions and methods for treatment of colorectal cancer
03/19/2009US20090074782 Compositions and Methods for Treating and Diagnosing Cancer
03/19/2009US20090074779 Neurotrophin-derived peptide sequences
03/19/2009US20090074764 Methods for diagnosing and treating neuroendocrine cancer
03/19/2009US20090074761 Therapeutic beta-glucan combinations
03/19/2009US20090074760 Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant
03/19/2009US20090074757 Antitumor Combination Comprising Substituted Acryloyl Distamycin Derivatives and Antibodies Inhibiting Growth Factors or Their Receptors
03/19/2009US20090074741 Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
03/19/2009US20090074724 Materials and methods for inhibiting wip1
03/19/2009US20090074722 Products and methods for treating PTP lar diseases
03/19/2009US20090074719 Peptides, Peptidomimetics and Small Molecule Inhibitors of the Epstein-Barr Virus Mediated Fusion and Entry Process
03/19/2009US20090074713 Dendritic cell tumor injection (dcti) therapy
03/19/2009US20090074711 Human therapies using chimeric agonistic anti-human cd40 antibody
03/19/2009US20090074710 Method of treatment using a cytokine able to bind il-18bp to inhibit the activity of a second cytokine
03/19/2009US20090074706 A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, prodrugs of (4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; anticarcinogenic agents
03/19/2009US20090074704 Multi-Arm Polymer Prodrugs
03/19/2009US20090074670 Hyperthermia Therapeutic Agent Delivery System
03/19/2009US20090074665 Diagnosis and treatment of cancer:I
03/19/2009US20090074664 Cyclic azapeptides as integrin markers
03/19/2009US20090074660 Human Monoclonal Antibodies To O8E
03/19/2009US20090074659 Cancerous disease modifying antibodies
03/19/2009CA2737126A1 Novel p2x7 epitopes
03/19/2009CA2731204A1 Use of a peptide as a therapeutic agent
03/19/2009CA2704726A1 Use of a defensin peptide as a therapeutic agent
03/19/2009CA2699794A1 Mitochondria-targeted anti-tumour agents
03/19/2009CA2699488A1 Conjugates of ribosome inactivating toxins with agents that bind to er+ cell receptors
03/19/2009CA2699222A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699215A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009CA2699202A1 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
03/19/2009CA2699167A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699040A1 Perharidines
03/19/2009CA2699038A1 Phthalazinone derivatives
03/19/2009CA2699026A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699020A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699012A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699010A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699008A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699006A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698992A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698985A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698984A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698981A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698980A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698978A1 Use of human neuropeptide af as a therapeutic agent
03/19/2009CA2698977A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent
03/19/2009CA2698976A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698974A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698971A1 Use of urodilatin as a therapeutic agent
03/19/2009CA2698966A1 Use of fertirelin and delta-endorphin as therapeutic agents
03/19/2009CA2698963A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698944A1 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
03/19/2009CA2698912A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698855A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698852A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698833A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698831A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698828A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698824A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
03/19/2009CA2698822A1 Minigastrin as a therapeutic agent
03/19/2009CA2698821A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698808A1 Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
03/19/2009CA2698792A1 Vegfr inhibitors containing a zinc binding moiety
03/19/2009CA2698786A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698783A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698778A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698770A1 Use of secretin and optionally urodilatin as a therapeutic agents
03/19/2009CA2698759A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698754A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698748A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698745A1 Use of a peptide as a therapeutic agent
1 ... 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 ... 2211